TARDBP and proteostasis deficiencies: Future validation studies should incorporate blood-based biomarkers like NfL, emerging cryptic exon-based approaches, and extracellular vesicle TDP-43 detection that demonstrate high sensitivity and specificity for TDP-43 proteinopathies [34,35].